Parallax Volatility Advisers
PVLA

Parallax Volatility Advisers’s Palvella Therapeutics PVLA Stock Holding History

Parallax Volatility Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-145
Closed -$59K – 3774
2018
Q2 		$59K Hold
145
– – ﹤0.01% 1532
2018
Q1 		$79K Sell
145
-96
-40% -$59.4K ﹤0.01% 1414
2017
Q4 		$145K Buy
241
+96
+66% +$44.6K ﹤0.01% 2541
2017
Q3 		$67K Hold
145
– – ﹤0.01% 1624
2017
Q2 		$59K Buy
+145
New +$42.4K ﹤0.01% 1761

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's PVLA Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Palvella Therapeutics (PVLA) in Q3 2018, closing a stake of 145 shares — an estimated $59K sold.

Parallax Volatility Advisers first reported a position in PVLA in Q2 2017 and held it in 5 quarters. The position peaked at $145K in Q4 2017. 105 funds tracked by Wall St. Rank hold PVLA as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Palvella Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 145 Palvella Therapeutics shares in Q3 2018, an estimated $59K.
  • Parallax Volatility Advisers first reported a position in Palvella Therapeutics in Q2 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Palvella Therapeutics position peaked at $145K in Q4 2017.
  • 105 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.